GenMark Dx ePlex 血培养革兰阳性菌鉴定 panel 的临床性能评估
本研究为多中心评估,比较研究用 ePlex BCID-GP Panel 与其他鉴定方法对 20 种革兰阳性菌、4 种耐药基因及 Pan Candida 和 Pan 革兰阴性靶标的检测性能,共测试 2,342 份可评估样本。总体上,病原体靶标的阳性符合率(PPA)和阴性符合率(NPA)分别可达 93.1%–100% 和 98.8%–100%,耐药基因的 PPA 为 96.8%–100%。结论认为该 panel 与标准方法及靶向分子方法具有较好的一致性。
要点
- 对致病性革兰阳性靶标,PPA 为 93.1%–100%,NPA 为 98.8%–100%。
- 对污染排除靶标,PPA 为 84.5%–100%,NPA 为 99.9%–100%。
- 耐药基因 mecA、mecC、vanA、vanB 的 PPA 分别为 97.2%、100%、96.8%、100%。
核心结论
- ePlex BCID-GP Panel 在阳性血培养瓶中鉴定 20 种革兰阳性病原体和 4 种耐药基因的性能与标准方法及靶向分子方法相当。
- 该 panel 可检测同一阳性血培养瓶中的混合感染,包括酵母和革兰阴性菌。
研究设计与样本
- 多中心研究,美国 10 家微生物实验室收集残留、去标识的阳性血培养样本。
- 5 家实验室同时测试临床样本和人工构建样本,共 2,342 份可评估样本(1,777 份临床样本和 565 份人工构建样本)。
- 对照方法包括各实验室的标准方法(MALDI-TOF MS 和自动鉴定系统)以及靶向 PCR/经分析验证的实时 PCR(qPCR)结合双向测序。
主要发现
- 在解决不一致结果前,panel 内病原体的总体样本准确率为 89%。
- 对致病性革兰阳性靶标,PPA 和 NPA 范围分别为 93.1%–100% 和 98.8%–100%。
- 对污染排除靶标,PPA 和 NPA 范围分别为 84.5%–100% 和 99.9%–100%。
- Pan Candida 靶标的 PPA 和 NPA 分别为 92.4% 和 95.7%;Pan 革兰阴性靶标的 PPA 和 NPA 分别为 99.9% 和 99.6%。
- 耐药标记的 PPA 分别为 mecA 97.2%、mecC 100%、vanA 96.8%、vanB 100%;NPA 范围为 96.6%–100%。
临床怎么用
- 该 panel 可用于阳性血培养瓶的快速鉴定,覆盖 20 种革兰阳性病原体和 4 种耐药基因。
- 可同时检测同一瓶中的酵母和革兰阴性菌混合感染,有助于早期调整抗菌治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid identification from positive blood cultures is standard of care (SOC) in many clinical microbiology laboratories. The GenMark Dx ePlex Blood Culture Identification Gram-Positive (BCID-GP) Panel is a multiplex nucleic acid amplification assay based on competitive DNA hybridization and electrochemical detection using eSensor technology. This multicenter study compared the investigational-use-only (IUO) BCID-GP Panel to other methods of identification of 20 Gram-positive bacteria, four antimicrobial resistance genes, and both Pan Candida and Pan Gram-Negative targets that are unique to the BCID-GP Panel. Ten microbiology laboratories throughout the United States collected residual, deidentified positive blood culture samples for analysis. Five laboratories tested both clinical and contrived samples with the BCID-GP Panel. Comparator identification methods included each laboratory's SOC, which included matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and automated identification systems as well as targeted PCR/analytically validated real-time PCR (qPCR) with bidirectional sequencing. A total of 2,342 evaluable samples (1,777 clinical and 565 contrived) were tested with the BCID-GP Panel. The overall sample accuracy for on-panel organisms was 89% before resolution of discordant results. For pathogenic Gram-positive targets (Bacillus cereus group, Enterococcus spp., Enterococcus faecalis, Enterococcus faecium, Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Listeria spp., Listeria monocytogenes, Streptococcus spp., Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus pneumoniae, and Streptococcus pyogenes), positive percent agreement (PPA) and negative percent agreement (NPA) ranged from 93.1% to 100% and 98.8% to 100%, respectively. For contamination rule-out targets (Bacillus subtilis group, Corynebacterium, Cutibacterium acnes, Lactobacillus, and Micrococcus), PPA and NPA ranged from 84.5% to 100% and 99.9% to 100%, respectively. Positive percent agreement and NPA for the Pan Candida and Pan Gram-Negative targets were 92.4% and 95.7% for the former and 99.9% and 99.6% for the latter. The PPAs for resistance markers were as follows: mecA, 97.2%; mecC, 100%; vanA, 96.8%; and vanB, 100%. Negative percent agreement ranged from 96.6% to 100%. In conclusion, the ePlex BCID-GP Panel compares favorably to SOC and targeted molecular methods for the identification of 20 Gram-positive pathogens and four antimicrobial resistance genes in positive blood culture bottles. This panel detects a broad range of pathogens and mixed infections with yeast and Gram-negative organisms from the same positive blood culture bottle.
引用
- Carroll KC, Reid JL, Thornberg A, et al. Clinical Performance of the Novel GenMark Dx ePlex Blood Culture ID Gram-Positive Panel. J Clin Microbiol. 2020. PMID: 31996444. doi:10.1128/JCM.01730-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。